Primary Biliary Cholangitis Pbc — Patent Landscape

Aggregated US Orange Book patent estate across every approved drug for primary biliary cholangitis pbc . 8 active patents protecting 1 drugs from 1+ originators. First major cliff: 2037. Daily refresh.

1
Approved drugs
8
Active US patents
75/100
Avg vulnerability
—
Annual revenue covered

Originators in Primary Biliary Cholangitis Pbc

Companies holding active patents on drugs approved for this indication. Click through to each company's full patent dashboard.

Ipsen 8 patents

Cliff calendar — next 15 years

Patent expiries per year across all drugs treating primary biliary cholangitis pbc . Each bar = one year. Y-axis scaled to peak year (8 patents).

8
37

Approved drugs ranked by patent estate

Drug Originator Active patents Avg vuln Revenue First cliff
Iqirvo
ELAFIBRANOR
 Ipsen 8 75 — 2037-03-30

Most attackable patents

Highest vulnerability scores in the indication — paragraph IV / IPR / design-around candidates.

Patent Drug Type Vuln Expiry
12310935 Iqirvo method of use 75 2037-03-30
12233038 Iqirvo method of use 75 2037-03-30
11331292 Iqirvo method of use 75 2037-03-30
11185519 Iqirvo method of use 75 2037-03-30
11857523 Iqirvo method of use 75 2037-03-30
11850223 Iqirvo method of use 75 2037-03-30
12295928 Iqirvo method of use 75 2037-03-30
12295927 Iqirvo method of use 75 2037-03-30

Strongest defences

Lowest vulnerability scores — pillars of the indication's IP fortress.

Patent Drug Type Vuln Expiry
12310935 Iqirvo method of use 75 2037-03-30
12233038 Iqirvo method of use 75 2037-03-30
11331292 Iqirvo method of use 75 2037-03-30
11185519 Iqirvo method of use 75 2037-03-30
11857523 Iqirvo method of use 75 2037-03-30
11850223 Iqirvo method of use 75 2037-03-30
12295928 Iqirvo method of use 75 2037-03-30
12295927 Iqirvo method of use 75 2037-03-30

Related